المؤلفون: Zeng Z; Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Maiti A; Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Herbrich S; Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Cai T; Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Cavazos A; Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Manzella T; Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Ma H; Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Hayes K; Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Matthews J; Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., DiNardo CD; Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Daver NG; Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Konopleva MY; Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

المصدر: Cancer [Cancer] 2023 Feb 15; Vol. 129 (4), pp. 531-540. Date of Electronic Publication: 2022 Dec 07.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents*/therapeutic use , Leukemia, Myeloid, Acute*, Humans ; Aged ; Methyltransferases ; Programmed Cell Death 1 Receptor/therapeutic use ; DNA Modification Methylases ; Proto-Oncogene Proteins c-bcl-2/genetics ; DNA/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects

المؤلفون: Maiti A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Qiao W; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kadia TM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Jabbour EJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Rausch CR; Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas., Daver NG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Yilmaz M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Alvarado Y; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Montalbano KS; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wade A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Maduike RE; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Guerrero JA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Vaughan K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Bivins CA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Pierce S; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ning J; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Konopleva MY; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.

المصدر: Cancer [Cancer] 2021 Nov 15; Vol. 127 (22), pp. 4213-4220. Date of Electronic Publication: 2021 Aug 03.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Leukemia, Myeloid, Acute*, Adult ; Bridged Bicyclo Compounds, Heterocyclic ; Cytarabine ; Decitabine ; Humans ; Propensity Score ; Sulfonamides

المؤلفون: Kim K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Maiti A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Loghavi S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Pourebrahim R; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kadia TM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Rausch CR; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Furudate K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Oral and Maxillofacial Surgery, Hirosaki University Graduate School of Medicine, Aomori, Japan., Daver NG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Alvarado Y; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ohanian M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Sasaki K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Takahashi K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Yilmaz M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Tang G; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Konopleva MY; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.

المصدر: Cancer [Cancer] 2021 Oct 15; Vol. 127 (20), pp. 3772-3781. Date of Electronic Publication: 2021 Jul 13.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Leukemia, Myeloid, Acute*/drug therapy , Leukemia, Myeloid, Acute*/genetics, Aged ; Aged, 80 and over ; Bridged Bicyclo Compounds, Heterocyclic/therapeutic use ; Decitabine/adverse effects ; Humans ; Middle Aged ; Sulfonamides ; Tumor Suppressor Protein p53/genetics

المؤلفون: Rausch CR; Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas., DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Maiti A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Jammal NJ; Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kadia TM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Marx KR; Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas., Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Savoy JM; Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas., Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., DiPippo AJ; Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas., Daver NG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Chew SM; Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas., Sasaki K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Issa GC; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Takahashi K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ohanian MN; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ning J; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Xiao L; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Alvarado Y; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kontoyiannis DP; Department of Infectious Diseases, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Konopleva MY; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.

المصدر: Cancer [Cancer] 2021 Jul 15; Vol. 127 (14), pp. 2489-2499. Date of Electronic Publication: 2021 Apr 01.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Leukemia, Myeloid, Acute* , Thrombocytopenia*/chemically induced , Thrombocytopenia*/drug therapy, Aged ; Antifungal Agents/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Azoles/therapeutic use ; Bridged Bicyclo Compounds, Heterocyclic ; Humans ; Sulfonamides

المؤلفون: Maiti A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Cortes JE; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Patel KP; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Masarova L; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Verstovsek S; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ferrajoli A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Estrov Z; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kadia TM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Nogueras-González GM; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Skinner J; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Poku R; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., DellaSala S; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Luthra R; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Jabbour EJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., O'Brien S; Chao Family Comprehensive Cancer Center, University of California, Irvine, California., Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.

المصدر: Cancer [Cancer] 2020 Apr 01; Vol. 126 (7), pp. 1502-1511. Date of Electronic Publication: 2020 Jan 30.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents/*therapeutic use , Dasatinib/*therapeutic use , Leukemia, Myeloid, Chronic-Phase/*drug therapy, Adult ; Female ; Follow-Up Studies ; Humans ; Leukemia, Myeloid, Chronic-Phase/mortality ; Male ; Middle Aged ; Survival Rate ; Time ; Treatment Outcome